Table 1. Baseline Characteristics of the Study Population.
| Characteristics | Patients |
| Age (years) | 76+-4 |
| Male | 99% |
| Primary Prophylaxis Indication | 75% |
| Secondary Prophylaxis Indication | 25% |
| Diabetes | 55% |
| Hypertension | 96% |
| Coronary Artery Disease | 86% |
| Atrial fibrillation | 35% |
| Left ventricular Ejection Fraction at time of Implantation | 28+-12 % |
| NYHA Class II | 27.3% |
| NYHA Class III | 39.3% |
| GFR at the time of implantation | 59+-24 ml/min |
| Beta Blockers | 78.2% |
| ACE-inhibitors/ARB | 79.2% |
| Spironolactone | 9.7% |
| Diuretics | 61.5% |
| Aspirin | 79.2% |
| Dual Antiplatelet Therapy | 20% |
| Anticoagulation | 29.1% |